Patents Assigned to ChemoCentryx, Inc.
  • Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
    Patent number: 7442512
    Abstract: The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: October 28, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Zhenhua Miao, Zheng Wei, Maureen C. Howard, Brett A. Premack, Thomas J. Schall
  • SUBSTITUTED PIPERAZINES
    Publication number: 20080261987
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: July 21, 2006
    Publication date: October 23, 2008
    Applicant: ChemoCentryx, Inc.
    Inventors: Andrew M.K. Pennell, James B. Aggen, J.J. Kim Wright, Subrabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi
  • Bicyclic and bridged nitrogen heterocycles
    Patent number: 7435830
    Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: October 14, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Andrew M. K. Pennell, James B. Aggen, J. J. Kim Wright, Subhabrata Sen, Wei Chen, Daniel Joseph Dairaghi, Penglie Zhang
  • Bicyclic and bridged nitrogen heterocycles
    Patent number: 7435831
    Abstract: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases, and as controls in assays for the identification of competitive receptor antagonists for the above chemokine receptors.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: October 14, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Wei Chen, Penglie Zhang, James B. Aggen, Daniel Joseph Dairaghi, Andrew M. K. Pennell, Subhabrata Sen, J. J. Kim Wright
  • Aryl sulfonamides
    Patent number: 7420055
    Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: September 2, 2008
    Assignee: Chemocentryx, Inc.
    Inventors: Solomon Ungashe, J. J. Wright, Andrew Pennell, Zheng Wei, Anita Melikan
  • Substituted arylamides
    Patent number: 7417062
    Abstract: Substituted benzamide compounds are provided along with methods for the use of those compounds for treating cancer.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: August 26, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Anita Melikian, John J. Kim Wright
  • Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
    Patent number: 7413866
    Abstract: The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of a chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: August 19, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Zhenhua Miao, Zheng Wei, Maureen C. Howard, Brett A. Premack, Thomas J. Schall
  • Cell migration assay
    Patent number: 7396653
    Abstract: The present invention is directed to a modified cell migration assay allowing for improved identification and discrimination of chemokine receptor antagonists from non-specific blockers.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: July 8, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Zheng Wei, Zhenhua Miao
  • Compositions for inducing an immune response
    Patent number: 7361329
    Abstract: This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for, among other things, vaccine formulation for therapeutic and prophylactic vaccination (immunization) and for production of useful antibodies (e.g., monoclonal antibodies for therapeutic or diagnostic use).
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: April 22, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Thomas J. Schall, Maureen Howard, Robert Berkovitz, Brett Premack, Dale Talbot
  • Bis-aryl sulfonamides
    Patent number: 7335653
    Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: February 26, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, John J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
  • CXCR4 modulators
    Publication number: 20070275965
    Abstract: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.
    Type: Application
    Filed: March 30, 2007
    Publication date: November 29, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: William Thomas, Manmohan Leleti, Andrew Pennell
  • CXCR4 MODULATORS
    Publication number: 20070254915
    Abstract: The present invention is directed to novel compounds and pharmaceutical compositions that inhibit the binding of the SDF-1 chemokine to the chemokine receptor CXCR4 and/or the binding of the SDF-1 or I-TAC chemokines to the chemokine receptor CCXCKR2 (CXCR7). These compounds are useful in preventing tumor cell proliferation, tumor formation, metastasis, inflammatory diseases, treatment of HIV infectivity, treatment of stem cell differentiation and mobilization disorders, and ocular disorders.
    Type: Application
    Filed: March 30, 2007
    Publication date: November 1, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Manmohan Leleti, William Thomas, Penglie Zhang, Andrew Pennell
  • Cell migration assay
    Patent number: 7282338
    Abstract: The present invention is directed to a modified cell migration assay allowing for improved identification and discrimination of chemokine receptor antagonists from non-specific blockers.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: October 16, 2007
    Assignee: ChemoCentryx, Inc.
    Inventors: Zheng Wei, Zhenhua Miao
  • Modulation of CCR4 function
    Patent number: 7262204
    Abstract: Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
    Type: Grant
    Filed: September 2, 2003
    Date of Patent: August 28, 2007
    Assignees: Amgen Inc., ChemoCentryx, Inc.
    Inventors: Tassie Collins, Daniel J. Dairaghi, Hossen Mahmud, Brian E. McMaster, Julio C. Medina, Thomas J. Schall, Feng Xu, Xuemei Wang
  • Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
    Patent number: 7253007
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: August 7, 2007
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
  • Substituted quinolones and methods of use
    Publication number: 20070167443
    Abstract: Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.
    Type: Application
    Filed: November 13, 2006
    Publication date: July 19, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Anita Melikian, John Wright, Antoni Krasinski, Cheng Hu, Aaron Novack
  • Substituted dihydropyridines and methods of use
    Publication number: 20070112015
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.
    Type: Application
    Filed: October 30, 2006
    Publication date: May 17, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Clarence Hurt, Andrew Pennell, John Wright, Manmohan Leleti, Qiang Wang, William Thomas, Yandong Li, Dean Dragoli
  • Piperidine derivatives and methods of use
    Publication number: 20070093467
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: October 11, 2006
    Publication date: April 26, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, Wei Chen, Kevin Greenman, Edward Sullivan, Lianfa Li
  • Piperidine derivatives and methods of use
    Publication number: 20070088036
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: October 11, 2006
    Publication date: April 19, 2007
    Applicant: ChemoCentryx, Inc.
    Inventors: Penglie Zhang, Andrew Pennell, Wei Chen, Kevin Greenman, Lianfa Li, Edward Sullivan
  • Methods for identifying modulators of CCX CKR activity
    Patent number: RE39849
    Abstract: The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the activity or expression of the receptors, as well as methods for detecting receptor expression.
    Type: Grant
    Filed: December 29, 2005
    Date of Patent: September 18, 2007
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifa Gosling, Daniel J. Dairaghi, Michael Hanley, Zhenhua Miao, Thomas J. Schall